Answers are grounded in this paper and cite their sources.
The severe impact of the coronavirus pandemic has indeed prompted several questions about economic and social security. Among them is placed the current concern about the possible nationalization of the U.S. pharmaceutical industry due to the fear of a possible generic drugs shortage. More importantly, since the United States imports most of its drugs from other countries (e.g. China), is the impact of Covid-19 on the pharmaceutical industry the catalyst for a future nationalization for the U.S. pharmaceutical industry? Are there real reasons to support this prospect, or is it an old argument renewed by fear?
No takes yet. Share an insight, caveat, or question.
Ferri et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: